DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics:
Current status and challenges. Pharmacogenetics,
2003, 13:525–534.
Kalow W, Tang BK, Endrenyi L. Hypothesis: Comparisons of
inter- and intra-individual variations can substitute for twin
studies in drug research. Pharmacogenetics, 1998, 8:
283–289.
Kim DW, Kim M, Lee SK, et al. Lack of association between
C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant
epilepsy. Seizure, 2006, 15:344–347.
Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism
in the MDR1 gene changes substrate specificity1.
Science, 2007, 315:525–528.
Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and
CYP2C19 genotype-based dose recommendations for antidepressants:
A first step towards subpopulation-specific dosages.
Acta Psychiatr Scand, 2001, 104:173–192.
Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C—>T polymorphism
and risk of coronary heart disease: A meta-analysis.
JAMA, 2002, 288:2023–2031.
Krajinovic M, Costea I, Chiasson S. Polymorphism of the
thymidylate synthase gene and outcome of acute lymphoblastic
leukaemia. Lancet, 2002, 359:1033–1034.
Kraus JP, Oliveriusova J, Sokolova J, et al. The human cystathionine
beta-synthase (CBS) gene: Complete sequence, alter -
native splicing, and polymorphisms. Genomics, 1998, 52:
312–324.
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters
and characterization of the genetic basis of polymorphic
CYP3A5 expression. Nat Genet, 2001, 27:383–391.
Leabman MK, Huang CC, DeYoung J, et al. Natural variation in
human membrane transporter genes reveals evolutionary and
functional constraints. Proc Natl Acad Sci USA, 2003,
100:5896–5901.
Lesko LJ. The critical path of warfarin dosing: Finding an optimal
dosing strategy using pharmacogenetics. Clin Pharmacol
Ther, 2008, 84:301–303.
Lesko LJ, Woodcock J. Opinion: Translation of pharmacogenomics
and pharmacogenetics: A regulatory perspective. Nat
Rev Drug Discov, 2004, 3:763–769.
Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of
CYP3A4 and CYP3A5 and contribution to hepatic and intestinal
midazolam metabolism. Mol Pharmacol, 2002, 62:162–
172.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness
of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004,
350:2129–2139.
Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation
of debrisoquine in man. Lancet, 1977, 2:584–586.
Mallal S, Nolan D, Witt C, et al. Association between presence
of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity
to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet,
2002, 359:727–732.
Mallal S, Phillips E, Carosi G, et al. Hla-b∗5701 screening for
hypersensitivity to abacavir. N Engl J Med, 2008, 358:
568–579.
McDonald OG, Krynetski EY, Evans WE. Molecular haplotyping
of genomic DNA for multiple single nucleotide polymorphisms
located kilobases apart using long range polymerase
chain reaction and intramolecular ligation. Pharmacogenetics,
2002, 12:93–99.
Meyer UA. Pharmacogenetics and adverse drug reactions.
Lancet, 2000, 356:1667–1671.
Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms
of drug metabolism. Annu Rev Pharmacol Toxicol,
1997, 37:269–296.
Miller MP, Kumar S. Understanding human disease mutations
through the use of interspecific genetic variation. Hum Mol
Genet, 2001, 10:2319–2328.
Mirkovic N, Marti-Renom MA, Weber BL, et al. Structure-based
assessment of missense mutations in human BRCA1:
Implications for breast and ovarian cancer predisposition.
Cancer Res, 2004, 64:3790–3797.
Monaghan G, Ryan M, Seddon R, et al. Genetic variation in
bilirubin upd-glucuronosyltransferase gene promoter and
gilbert’s syndrome. Lancet, 1996, 347:578–581.
Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF.
Pharmacogenetics of antidepressant medication intolerance.
Am J Psychiatry, 2003, 160:1830–1835.
Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing
enzyme polymorphisms: Effects on risk of toxicity and cancer.
DNA Cell Biol, 1996, 15:273–280.
Ng LC, Forslund O, Koh S, et al. The response of murine
macrophages to infection with Yersinia pestis as revealed by
DNA microarray analysis. Adv Exp Med Biol, 2003, 529:
155–160.
Pani MA, Knapp M, Donner H, et al. Vitamin D receptor allele
combinations influence genetic susceptibility to type 1 diabetes
in germans. Diabetes, 2000, 49:504–507.
Parsons AB, Brost RL, Ding H, et al. Integration of chemicalgenetic
and genetic interaction data links bioactive compounds
to cellular target pathways. Nat Biotechnol, 2004,
22:62–69.
Penno MB, Dvorchik BH, Vesell ES. Genetic variation in rates
of antipyrine metabolite formation: A study in uninduced
twins. Proc Natl Acad Sci USA, 1981, 78:5193–5196.
Phillips KA, Veenstra DL, Oren E, et al. Potential role of
pharmacogenomics in reducing adverse drug reactions: A systematic
review. JAMA, 2001, 286:2270–2279.
Ramensky V, Bork P, Sunyaev S. Human non-synonymous
SNPs: Server and survey. Nucleic Acids Res, 2002, 30:
3894–3900.
Redon R, Ishikawa S, Fitch KR., et al. Global variation in copy
number in the human genome. Nature, 2006, 444:444–454.
Relling MV, Dervieux T. Pharmacogenetics and cancer therapy.
Nature Rev Cancer, 2001, 1:99–108.
Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine
therapy intolerance and heterozygosity at the thiopurine S-
methyltransferase gene locus. J Natl Cancer Inst, 1999,
91:2001–2008.
Roden DM. Cardiovascular pharmacogenomics. Circulation,
2003, 108:3071–3074.
Roden DM. Drug-induced prolongation of the QT interval. N Engl
J Med, 2004, 350:1013–1022.
Rosenberg NA, Li LM, Ward R, Pritchard JK. Informativeness of
genetic markers for inference of ancestry. Am J Hum Genet,
2003, 73:1402–1422.
Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure
of human populations. Science, 2002, 298:2381–2385.
167
CHAPTER 7
PHARMACOGENETICS